Dicerna Pharmaceuticals, Inc.: Series B $25M

Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - RNAi, XX - MA

Dicerna Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on the development RNAi-based therapeutics, closed a $25M Series B financing. Participants include Domain Associates, Oxford Bioscience Partners, Abingworth Management and Skyline Ventures.

Metamark Genetics, Inc.: Series B $22M

Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - Device (Diagnostic), X - Oncology, XX - MA

Metamark Genetics (Cambridge, MA) a development-stage molecular diagnostics company focused on prognostic assays for early-stage cancers, closed a $22M Series B financing. Participants may have included Perseus.

Visterra, Inc.: Series A $6M

Posted in I - Series A, Q - 3Q10, R - NORTH WEST, X - Antiviral, X - Influenza, X - Vaccines, XX - MA

Visterra (Cambridge, MA) a development-stage company focused virus-glycan docking to derive products for the prevention, treatment and diagnosis of influenza and other infectious diseases, closed a $6M Series A financing. Participants include Flagship Ventures, Lux Capital and Polaris Venture Partners.

SynapDx Corp.: Series A $9M

Posted in I - Series A, Q - 2Q10, R - NORTH EAST, X - Autism, X - Device (Diagnostic), XX - MA

SynapDx (Waltham, MA) a development-stage diagnostic company focused on the early detection of autism, closed a $9M Series A financing. Participants include Bain Capital Ventures, General Catalyst Partners and North Bridge Venture Partners.

BioScale, Inc.: Series D $25M

Posted in I - Series D, Q - 2Q10, R - NORTH EAST, X - Device (Diagnostic), X - Device (Protein Assay), XX - MA

BioScale (Cambridge, MA) a commercial-stage therapeutic and diagnostics protein biomarker analytics device company, closed a $25M Series D financing. Participants include Morningside Venture, New Science Ventures, WFD Ventures and F2 Ventures.

Stemgent, Inc.: Series B $5.6M

Posted in I - Series B, Q - 2Q10, R - NORTH EAST, X - Reagent, X - Stem Cell, XX - MA

Stemgent (Cambridge, MA) a commercial-stage supplier of stemcell related reagents and tools, closed a $5.6M Series B financing. Participants include HealthCare Ventures and Morgenthaler Ventures.

Inotek Pharmaceuticals Corp.: Series D $18M

Posted in I - Series D, Q - 2Q10, R - NORTH EAST, X - Opthalmology, XX - MA

Inotek Pharmaceuticals (Lexington, MA) a clinical-stage small molecule company focused on age-related macular degeneration, glaucoma, cataract and diabetic retinopathy, closed a $18M Series D financing. Participants include Devon Park Bioventures, Rho Ventures, Care Capital, Pitango Venture Capital, MedImmune Ventures and Bio One Capital.

MedVentive, Inc.: Series C $2.8M

Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Bioinformatics, X - TeleMedicine, XX - MA

MedVentive (Waltham, MA) a commercial-stage electronic medical data company, closed a $2.8M Series C, bring the entire financing to $10M. Participants include HLM Venture Partners, Excel Venture Management, Clarian Health Ventures, Core Capital Partners and Long River Ventures.

BIND Biosciences, Inc.: Series C $12.4M

Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Cardiology, X - Inflammation, X - Oncology, X - Therapeutic Platform, XX - MA

Bind Biosciences (Cambridge, MA) a preclinical-stage nanoparticle platform company focused on increased efficacy and reduced toxicity of currently marketed drugs, closed a $12.4M Series C financing. Participants include Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments and Endeavour Vision.

Joule Biotechnologies, Inc.: Series B $30M

Posted in I - Series B, Q - 2Q10, R - NORTH EAST, X - Biofuel, XX - MA

Joule Biotechnologies (Cambridge, MA) a development stage company focused on the conversion of carbon dioxide into ethanol, closed a $30M Series B financing. Participants include Flagship Ventures.

« Previous Entries

to top of page...